Future research could compare: Whether semaglutide works better than other GLP-1 drugs in reducing fibroid risks
doi: 10.1371/journal.pone.0077284 [DOI] [PMC free article] [PubMed] [Google Scholar] Egecioglu E, Engel JA, Jerlhag E
If you or a loved one is managing both type 2 diabetes and CKD, consult your doctor to learn more about this newly expanded treatment option
Currently available treatment with proven outcomes Semaglutide FDA-approved for diabetes (Ozempic), obesity (Wegovy), and CV risk reduction with 7+ years of clinical and post-marketing data Cardiovascular risk reduction Semaglutide SELECT trial demonstrated 20% MACE reduction in 17,604 patients -- the first anti-obesity drug with proven cardiovascular benefit Maximum weight loss potential Retatrutide Phase 2 data showed 24.2% weight loss at 48 weeks with weight curves still declining, though Phase 3 confirmation is required Metabolic liver disease (MASLD/MASH) Retatrutide Glucagon receptor agonism directly promotes hepatic fat oxidation, a mechanistic advantage for liver-specific outcomes Oral administration preference Semaglutide Only incretin-class drug available as an oral tablet (Rybelsus), with higher-dose oral formulations under development Type 2 diabetes with established treatment guidelines Semaglutide Integrated into clinical guidelines with multiple approved doses and formulations, extensive comparative data, and guideline positioning Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly
Now I understand that my body is resetting
As a recognized weight loss clinic in Carlsbad that accepts insurance, we aim to make treatment convenient and accessible for everyone
